Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × B-cell Malignancies × zanubrutinib × Clear all

Phase

Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 4 Lymphoma, Mantle-Cell 3 Recurrence 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Lymphoma, B-Cell, Marginal Zone 2 Waldenstrom Macroglobulinemia 1 Neoplasms 1 Lymphoma, B-Cell 1 Lymphoma 1 Leukemia 1 Hematologic Neoplasms 1 B-cell Malignancies 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02343120 2022-04-28

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

BeiGene

Phase 1/2 Completed

385 enrolled 29 charts 2 FDA

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡